Get the Stockscreener App
1.36
17.07%
-0.28
MAIA Biotechnology Inc stock is traded at $1.36, with a volume of 1.90M.
It is down -17.07% in the last 24 hours and up +27.10% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.64
Open:
$1.73
24h Volume:
1.90M
Relative Volume:
2.66
Market Cap:
$50.36M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-0.9855
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+13.33%
1M Performance:
+27.10%
6M Performance:
-22.29%
1Y Performance:
-32.34%
1-Day Range:
$1.34
$1.75
1-Week Range:
$1.16
$1.75
52-Week Range:
$0.87
$2.74
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.36 | 60.73M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Announces Significant Insider Buying - TipRanks
MAIA Biotechnology, Inc. Announces Key Developments in Cancer Therapy - TradingView — Track All Markets
MAIA Biotechnology (NYSE American: MAIA) begins Phase 3 NSCLC study of telomere-targeting ateganosine - Stock Titan
MAIA Biotechnology (MAIA) doses first patient in THIO-104 Phase 3 NSCLC trial - Stock Titan
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential - GlobeNewswire
MAIA Biotechnology announces significant insider buying - MSN
MAIA Biotechnology Advances NSCLC Treatment with Ateganosine - TipRanks
MAIA Biotechnology, Inc. Targets $50B Immunotherapy Market with New Approach - TradingView — Track All Markets
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - The Manila Times
MAIA Biotechnology (NYSE American: MAIA) starts Phase 3 telomere drug trial in NSCLC - Stock Titan
Prepare Yourself for Liftoff: MAIA Biotechnology Inc (MAIA) - setenews.com
Director Makes Bold Move with Major Stock Purchase in MAIA Biotechnology! - TipRanks
Can MAIA Biotechnology Inc. stock sustain revenue momentum2025 Price Targets & Real-Time Price Movement Reports - Newser
How MAIA Biotechnology Inc. stock reacts to bond yieldsWeekly Gains Summary & Free Technical Pattern Based Buy Signals - Newser
Vlad Vitoc, Maia Biotech CEO, buys $79,848 in Maia stock By Investing.com - Investing.com Australia
Vlad Vitoc, Maia Biotech CEO, buys $79,848 in Maia stock - Investing.com
Is MAIA Biotechnology Inc. stock among top earnings plays2025 Stock Rankings & Daily Chart Pattern Signals - Newser
How MAIA Biotechnology Inc. stock compares with top peersMarket Trend Summary & Fast Gain Swing Alerts - Newser
Why hedge funds are buying MAIA Biotechnology Inc. stockRisk Management & Daily Risk Controlled Trade Plans - Newser
MAIA Biotechnology Inc (MAIA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
How MAIA Biotechnology Inc. stock responds to policy changesTrade Analysis Report & Daily Risk Controlled Trade Plans - Newser
Will MAIA Biotechnology Inc. stock return to pre crash levels2025 Bull vs Bear & Smart Allocation Stock Reports - Newser
How MAIA Biotechnology Inc. stock compares with market leaders2025 Technical Overview & Weekly High Return Stock Forecasts - Newser
Will MAIA Biotechnology Inc. stock recover faster than industryAnalyst Upgrade & Safe Entry Zone Tips - Newser
Why MAIA Biotechnology Inc. stock could rally stronglyJuly 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - Newser
Top Executives Make Bold Moves with Major Stock Purchases at MAIA Biotechnology! - TipRanks
Maia Biotechnology announces open market purchases by CEO and directors - marketscreener.com
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors - The Manila Times
Vitoc Vlad buys MAIA biotechnology (MAIA) shares worth $79,848 By Investing.com - Investing.com Australia
Luput Cristian, director at Maia Biotechnology, buys $41,845 in shares By Investing.com - Investing.com South Africa
Smith Stan, MAIA Biotechnology director, buys $15,582 in shares By Investing.com - Investing.com South Africa
Vitoc Vlad buys MAIA biotechnology (MAIA) shares worth $79,848 - Investing.com India
Smith Stan, MAIA Biotechnology director, buys $15,582 in shares - Investing.com
MAIA Biotechnology Executives Increase Holdings - TradingView — Track All Markets
Luput Cristian, director at Maia Biotechnology, buys $41,845 in shares - Investing.com
MAIA Biotechnology Inc Stock Analysis and ForecastMACD Histogram Signals & Affordable Market Trading - earlytimes.in
CEO’s Bold Move: Major Stock Purchase at MAIA Biotechnology! - TipRanks
Luput Cristian, director at Maia Biotechnology, buys $9,785 in shares By Investing.com - Investing.com Australia
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Cap:
|
Volume (24h):